lifestyle.newsblaze.com

Author: Tessera Therapeutics

Tessera Therapeutics Receives Grant to Advance In Vivo Gene Writing Approaches Towards a Potential Human Immunodeficiency Virus (HIV) Cure

March 23, 2026
Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the Treatment of Adults with AATD

February 23, 2026